LymphoPro Feline DxTM, patent pending, was developed in collaboration with Dr. Jörg M. Steiner of Texas A&M University and Dr. Sina Marsilio of UC Davis. This test employs histology guided mass spectrometry (HGMS) profiling and provides additional molecular data to help the veterinarian more accurately differentiate between intestinal small cell lymphoma and inflammatory bowel disease in cats.
Dr. Steiner and Dr. Marsilio recently authored a white paper that discusses the definitive diagnosis of cats with chronic enteropathy. The white paper covers the issues at hand, the limitations of currently available tests, and the diagnostic benefits of HGMS.
Chronic gastrointestinal disease with weight loss, vomiting, diarrhea, or other clinical signs is very common in cats, but definitive diagnosis remains challenging. Over the last decade, histopathology followed by immune-histochemistry and PARR (PCR for Antigen Receptor Rearrangement) has been proposed as the new gold standard for differentiating small cell lymphoma and idiopathic inflammatory bowel disease in cats. However, a recent study has shown that, as in people1, IHC and PARR are not specific for small cell lymphoma in cats.2 Histology guided mass spectrometry (HGMS) offers a new diagnostic modality for the definitive diagnosis of cats with chronic enteropathy.3
To read more, including a discussion of the following, click on the link below.
- How can HGMS help in my work-up of cats with clinical signs of chronic gastrointestinal disease?
- What is HGMS and how does it work?
- How well does HGMS perform and how does it compare to the currently available PARR test?